



**The Drug Utilization Review (DUR) Board Reviewed
the Following New Drugs/Classes on
January 22, 2025**

Therapeutic Class	Drug Name	DURB Recommendation*
Hemophilia Treatments		
	<i>Beqvez (Intravenous) Suspension</i>	P/PA or NP/PA pending further financial analysis
Duchenne Agents		
	<i>Duvyzat (Oral) Suspension</i>	NP/PA
Leukodystrophy Agents		
	<i>Lenmeldy (Intravenous) Suspension</i>	P/PA on PADL
Pulmonary Arterial Hypertension Agents		
	<i>Winrevair (Subcutaneous) Powder for Solution for Injection</i>	NP/PA

*All recommendations apply to the PDL unless explicitly stated otherwise; DURB=Drug Utilization Review Board; P=preferred; NP=non-preferred; PA=prior authorization; PDL=Preferred Drug List; PADL=Providers' Administered Drug List